Related Experiment Videos
[Pharmacokinetic, bacteriological and clinical studies on meropenem in children]
Abstract:
Pharmacokinetic, bacteriological and clinical studies on meropenem (MEPM) were performed in children. The results are summarized as follows: 1. A total of 16 patients was treated with MEPM. Each dose was 20 mg/kg, and administration was made 3 times daily using 30-minute intravenous drip infusion for 5-28 days. Clinical efficacies of MEPM in 16 patients with bacterial infections (1 with purulent meningitis, 1 with suspected subdural abscess, 2 with suspected sepsis, 4 with pneumonia, 1 with acute maxillar sinusitis, 2 with cervical abscess, 1 with acute gastroenteritis, 2 with skin soft tissue infection and 2 with urinary tract infection) were evaluated as excellent in 7 patients, good in 8 patients and fair in 1 patient with an efficacy rate of 93.8%. Fourteen causative organisms found in 11 patients (Streptococcus pneumoniae in 4, Branhamella catarrhalis in 3, Staphylococcus aureus in 3, Group B Streptococcus in 1, Escherichia coli in 3) were all eradicated. No adverse reactions were observed in any of the 16 patients. 2. MICs of MEPM against 6 clinically isolated bacteria (B. catarrhalis 2, S. pneumoniae 3 and S. aureus 1) from children with bacterial infections were examined. MEPM showed good antibacterial activities. 3. Pharmacokinetic studies: Peak plasma concentrations of MEPM averaged 43.07 micrograms/ml (37.20-46.30 micrograms/ml) at dose of 20 mg/kg administered by 30-minute drip infusion. In the first 8 hours after administration, the urinary excretion rates of MEPM averaged 39.9% of the administered dose.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Meropenem (MEPM) demonstrated a 93.8% clinical efficacy rate in children with bacterial infections, eradicating pathogens with no observed adverse reactions. Pharmacokinetic studies confirmed good antibacterial activity and predictable drug levels in pediatric patients.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Microbiology
Background:
- Bacterial infections pose a significant threat to pediatric health.
- Effective and safe antimicrobial agents are crucial for treating pediatric bacterial infections.
- Meropenem (MEPM) is a broad-spectrum carbapenem antibiotic with potential utility in pediatric populations.
Purpose of the Study:
- To evaluate the clinical efficacy, safety, bacteriological response, and pharmacokinetics of meropenem (MEPM) in pediatric patients.
- To assess the in vitro antibacterial activity of MEPM against common pediatric bacterial pathogens.
Main Methods:
- A clinical study involving 16 pediatric patients treated with MEPM (20 mg/kg, 3 times daily, 30-minute IV infusion for 5-28 days).
- Bacteriological assessment included eradication of causative organisms and in vitro Minimum Inhibitory Concentration (MIC) testing.
- Pharmacokinetic analysis involved measuring peak plasma concentrations and urinary excretion rates.
Main Results:
- MEPM showed an overall clinical efficacy rate of 93.8% (7 excellent, 8 good, 1 fair) across various infections including meningitis, sepsis, pneumonia, and UTI.
- Fourteen causative organisms from 11 patients were eradicated, with no adverse reactions reported in any of the 16 patients.
- MEPM exhibited good in vitro antibacterial activity against key pediatric pathogens (e.g., Streptococcus pneumoniae, Branhamella catarrhalis, Staphylococcus aureus) and favorable pharmacokinetic parameters.
Conclusions:
- Meropenem (MEPM) is a safe and effective treatment option for a range of bacterial infections in children.
- The drug demonstrates potent bactericidal activity and predictable pharmacokinetic behavior in the pediatric population.
- Further investigation into MEPM's role in pediatric infectious disease management is warranted.